Antares Pharma Announces Epinephrine Auto-Injector Settlement Agreement Between Teva and Pfizer

Antares Pharma, Inc. AIS today announced that Meridian Medical Technologies, a Pfizer PFE subsidiary, has entered into a settlement agreement with Teva TEVA , Antares' pharmaceutical partner, that will resolve pending patent litigation related to its abbreviated new drug application for a generic epinephrine auto-injector. According to the terms of the settlement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Additional terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.